Risk Factors Associated with Suboptimal Real-World Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Treated with Front-Line Recommended Therapy
More than 90% of the assessed real-world patients with EGFR-mutated (ex19del/L858R) NSCLC who received 1L osimertinib had risk factors associated with suboptimal outcomes, highlighting the urgent unmet need for new treatments and emphasizing the importance of administering the most effective therapy in the 1L setting.
Authors
- Alexander I. Spira (ORCID: https://orcid.org/0000-0003-1303-0447)
- Shawn Du (ORCID: https://orcid.org/0000-0003-2896-7873)
- Andy He (ORCID: https://orcid.org/0000-0003-4192-2979)
- Iris Lin
- Neel Belani (ORCID: https://orcid.org/0009-0004-8441-0855)
- Cindy Chen (ORCID: https://orcid.org/0000-0002-5358-7349)
- Ran Tao (ORCID: https://orcid.org/0000-0002-9296-3992)
Institutions
- Johnson & Johnson (United States) (US)
- Virginia Cancer Specialists (US)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2025-05-29
- DOI
- https://doi.org/10.1007/s12325-025-03234-3
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.52